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Background: Plasmodium falciparum and HIV-1 infection cause substantial morbidity and mortality in sub-Saharan
Africa. Increasing evidence suggests these two pathogens interact negatively when infecting the same individual.
Methods: A cross-sectional study among HIV-1 infected and uninfected populations was recruited in Mocuba and
Maputo, Mozambique to determine the prevalence of sub-clinical malarial parasitaemia using light microscopy and
a nested PCR assay.
Results: The prevalence of sub-clinical P. falciparum parasitaemia was low in Maputo, whether determined by
microscopy (0.4%) or PCR (1.9%), but substantially higher in Mocuba (7.6 and 14.7%, respectively). Nested PCR
detected nearly 70% more cases of sub-clinical parasitaemia than microscopy, but differences occur by locality.
HIV-1 infected persons were more likely to be sub-clinically parasitaemic than HIV-1 uninfected individuals recruited
from the same geographic areas. Trimethoprim-sulphamethoxazole use did not substantially reduce sub-clinical
parasitaemia.
Conclusions: Dried blood spots are a convenient and sensitive technique for detecting sub-clinical infection
with P. falciparum by nested PCR. Prevalence of P. falciparum is substantially lower in Maputo where malaria
control programmes have been more active than in the rural town of Mocuba. In Mocuba, among those
presenting for HIV-1 counseling and testing, the prevalence of P. falciparum is substantially higher in those who
test positive for HIV-1 than those without HIV-1 infection. The clinical implications of sub-clinical P. falciparum
infection among HIV-1 infected persons warrant additional study.
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Malaria and HIV each cause substantial morbidity and
mortality in sub-Saharan Africa, where they extensively
overlap geographically. It is estimated that in 2009 ap-
proximately 2.5 million deaths were attributable to mal-
aria and/or HIV-1 infection [1,2]. Although it was
initially thought that the two epidemics were* Correspondence: rschooley@ucsd.edu
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distribution, and reproduction in any mediumindependent, more recent studies demonstrate that these
two pathogens negatively impact each other from several
perspectives [3-5]. During clinically apparent bouts of
Plasmodium falciparum infection, plasma HIV RNA
levels increase [6]. CD4+ T lymphocytes decline tempor-
arily during clinical malaria episodes in both HIV-
infected and uninfected patients [7]. Repeated malaria
infections are associated with a more rapid decline in
CD4+ T lymphocyte counts over time in HIV-1 infected
individuals. These findings suggest that symptomatic P.
falciparum infections may accelerate progression of HIV
disease [7]. Conversely, recent studies indicate thatCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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advanced disease, are at greater risk for clinical malaria
[8,9]. In addition, bouts of clinical malaria in HIV-
infected patients, are more likely to be associated with
increased morbidity and mortality and higher relapse
rates following therapy [10].
Over the past several years, Mozambique’s national
malaria control programme has increased its efforts to
reduce morbidity and mortality from malaria. These
efforts have included intra-domiciliary spraying, the dis-
tribution of impregnated bed nets (especially for preg-
nant women and children below five years of age), and
intermittent chemoprophylaxis in pregnant women.
These measures have contributed to reductions in
malaria-related morbidity and mortality, especially in
urban areas of the country. Clinical cases of malaria
reported to Mozambique’s Ministério da Saúde (Ministry
of Health) declined from 6,155,082 in 2007 to 4,091,614
by 2009. Also, deaths attributed to malaria decreased
from 3,889 to 2,311 over the same time interval [11,12].
Despite these reductions, malaria remains a major cause
of morbidity and mortality in Mozambique, especially
among women and children, and still accounts for 44%
of outpatient visits, 57% of pediatric admissions and 26%
of all hospital admissions [13].
Mozambique also ranks among the top tier of coun-
tries in HIV-1 with an estimated adult prevalence rate
of 14% (in those 15-49 years of age)[14]. Mozambique,
therefore, serves as an excellent venue in which to fur-
ther delineate interactions between these two patho-
gens. The prevalence of sub-clinical malaria (which is
defined as having microbiological evidence of infection
without any clinical symptoms) was studied in two
locations in Mozambique. This study was conducted in
an effort to better understand the prevalence of sub-
clinical P. falciparum parasitaemia in two representa-
tive locations within Mozambique by blood smear and
by polymerase chain reaction (PCR) technology. In
addition, the study examined whether sub-clinical




This was a prospective cross-sectional study designed to
determine the prevalence of sub-clinical malaria in HIV-
1 infected and uninfected control volunteers residing in
similar locations. In addition, relationships among mal-
arial parasitaemia, HIV status and anti-malarial interven-
tion efforts were examined.
Study sites and populations sampled
Study participants were recruited from two hospitals in
Maputo (the Polana Caniço Hospital and the MaputoMilitary Hospital) and from the Mocuba District Hos-
pital, which served as a representative rural location in
Zambeze province.
Enrollment procedures and sample collection
Volunteers who were at least 18 years of age and seeking
care or voluntary testing for HIV-1 were recruited for
this study. Prior to enrollment, a nurse or HIV counselor
explained the study to participants and invited their par-
ticipation. Volunteers who agreed to participate and pro-
vided written informed consent were enrolled into the
study. The National Bioethics Committee of Mozam-
bique and the Human Research Protections Program of
the University of California, San Diego, approved the
study. Demographic and clinical data including gender,
age, CD4 cell count, HIV-1 treatment history and the
use of selected concomitant medications (including
trimethoprim-sulphamethoxazole [TS] were recorded.
Patients were also asked if they had received therapy for
malaria and, if so, how recently and what drug was
administered. Capillary blood was obtained by finger
stick from those seeking HIV testing. One spot of blood
was put onto a slide, stained with Giemsa and examined
by optical microscopy [15]. Approximately fifty uL of
blood was also placed on Whatman # 2 filter paper and
allowed to air dry. The blood spot was then fixed in
methanol and air dried prior to storage at 4°C until ship-
ment to San Diego, where they were stored at -20° C
until processing for PCR.Detection of P. falciparum DNA by PCR
Half of each blood spot was used to extract DNA using
a saponin/chelex extraction. Briefly, the DBS was placed
in 0.5% saponin in PBS over night at 4° C. The next day
the saponin solution was aspirated and replaced with
1 mL of PBS and placed at 4° C for 15-30 minutes. The
DBS was then placed into pre-heated 5% Chelex water
solution, vortexed and incubated for 10 minutes at
100°C. Vortexing was repeated five minutes through the
incubation, and at the end of the incubation. Tweezers
were used for all transfers of the DBS between tubes and
were flamed between each transfer. The DBS/Chelex so-
lution was then centrifuged at 10,000 g for 2 min and
the supernatant was moved to a new tube and was either
used for PCR or stored at -20°C.
The PCR for P. falciparum detects a 700 bp portion of
the Merozoite Specific Protein 2 (msp2) gene. Reactions
were performed using 2μL of supernatant from the DBS
DNA extraction in a 50μL PCR reaction (2.5 U Taq poly-
merase [Invitrogen], 3 mM MgCl2, 500nM dNTPs [Fer-
mentas], and 50 pmol of each primer [IDT]). In the first
round of the nested PCR, the gene was amplified using pri-
mers msp2_1F (5’-GAAGGTAATTAAAACATTGTC-3’)
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For the PCR, denaturation was performed at 94° C for
5 minutes, followed by 30 cycles of denaturation at 94°C
for 30 seconds, annealing at 55° C for 2 minutes, and
elongation at 70°C for 2 minutes, with a final extension at
72° C for 7 minutes. 1μL of the outer PCR product was
used as the template for the inner PCR reaction using pri-
mers MSP2_2F (5’-GAGTATAAGGAGAAGTATG-3’) and
MSP2_2R (5’-CTAGAACCATGCATATGTCC-3’), using
the same reaction times and temperatures. The PCR pro-
ducts from the inner PCR were run on a 1% agarose gel at
175 V for 30 minutes and stained with ethidium bromide
for visualization.
Detection of malarial parasites by light microscopy
Two independent microscopists read the smears for
malaria parasites. A third microscopist who was blinded
to the original results examined slides with discordant
results and the final results of the parasitaemia were the
average of the two similar counts. Results were
expressed as the number of visible parasites/μL blood.
HIV testing
HIV testing was performed in parallel with two rapid
HIV antibody detection kits (Determine [Abbott Labora-
tories] and Unigold [Trinity Biotech]).
Data analysis
Data were analysed using EPI INFO (version 3.4.3-CDC-
Atlanta). Continuous variables were compared using
Student’s t tests for variables not normally distributed.
Proportions were compared using the X2 test or the
Fisher’s exact test. A 2-tailed P value of ≤ 0.05 was
judged to be significant. Univariate and stratified ana-
lyses of data on age, sex, parasite density, and HIV seros-
tatus, use of TS, antiretroviral therapy regimen (ART)
and fever, CD4 cell count were conducted to identify po-
tential confounders and effect modifiers of the associa-
tions between the two pathogens. Statistical measure of




The algorithm shown in Figure 1 presents the overall
screening for HIV and malaria testing of the entire study
population. Overall 1,835 persons were recruited (Ma-
puto, n = 1,115, and Mocuba n= 720) of whom 1,280
(69.8%) were HIV infected and 555 (30.2%) were HIV
seronegative. The mean age of the study population was
32.6 years (range, 18 – 79) for the HIV infected cohort
and 30.7 years (range, 18 – 66) for the uninfected co-
hort. The HIV infected cohort was 64% female and 36%
male.Table 1 summarizes the prevalence of P. falciparum by
microscopy and the prevalence of P. falciparum DNA by
nested PCR by location. A greater proportion of those
recruited in Maputo (78.6%) than Mocuba (56.1%) were
HIV-1 infected.
Blood smears from all 1,835 study participants were
examined by light microscopy for malarial parasites and
the results are presented in Table 1. PCR for P. falcip-
arum DNA was performed on a subset of 1249 (68.1%)
of the study population. The overall prevalence of mal-
aria by microscopy was higher in Mocuba than in Ma-
puto (5.1% vs. 0.4%, p <0.001). Likewise P.m falciparum
DNA was detected more frequently in Mocuba (53 of
387 study participants, 14.7%) than in Maputo (16 of
862 study participants (1.9%) (p = 0.001).
Comparison of parasitaemia rates in the HIV-1 infected
and uninfected populations
In Mocuba, blood smear positivity for P. falciparum was
significantly higher among HIV infected individuals
compared to HIV uninfected individuals [39/404 (9.9%)
vs. 16/316 (5.1%), p <0.02]. Although the same trend to-
ward a higher prevalence of malaria in the HIV infected
population than in the uninfected population was noted
when assessed by PCR [(37/204, 18.2%) and (20/183,
10.9%)], the difference did not reach statistical signifi-
cance (p < 0.1). In Maputo only 0.5% of the 1115 study
participants were smear positive for P. falciparum and
only 16 of the 862 (1.8%) had detectable P. falciparum
DNA in plasma. In those with blood smears that were
positive for malarial parasites, there was a trend toward
a higher mean parasitaemia level in HIV-1 infected study
participants (11786 ± 28267 parasites/μl) compared to
those who were not infected with HIV-1 (2425 ± 4701
parasites/μl) (p = 0.08).
Impact of TS and ART use on parasitaemia
National HIV treatment guidelines at the time of the
study recommended that HIV-1 infected persons with
<250 CD4 cells/mm3 be prescribed chronic TS prophy-
laxis. During the period of the study, however, TS was
out of stock in Maputo and thus few Maputo partici-
pants received the drug. In Mocuba information about
TS prophylaxis was available for 397 of the 404 partici-
pants whose blood smears were examined for parasites
and from 201 of the 204 examined by PCR (Table 2).
Parasitaemia rates were similar by smear 10.7 vs. 8.4%
for those on TS prophylaxis compared to those not on
TS respectively. Similarly, P. falciparum DNA was
detected at a similar rate in the two groups (14.3 vs.
17.9%) respectively. Information about antiretroviral
therapy status and malarial positivity was available
for 335 participants from Mocuba. Parasitaemia rates
were similar between those who reported receiving
Figure 1 - Testing algorithm for study participants.
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ing use of antiretroviral drugs (30/248, 12%).
Comparison of the sensitivity and Kappa index of light
microscopy and PCR
Using visual inspection of the peripheral blood smear as
the gold standard reference for malaria parasiteTable 1 Frequency of positivity for Plasmodium falciparum by
nested PCR by location
Maputo n= 1115
n (%)




















Negative 846 (96.5)detection, the sensitivity and specificity of PCR is pre-
sented in Table 3. There is a substantial agreement be-
tween the smear and PCR for detection of malaria
k = 0.646 [0.543-0.748]. Indeed, the efficiency of PCR for
a positive or negative result is 97%. Overall, PCR
detected malarial parasitaemia in 73 of 1249 (5.8%) study
participants compared to 60 of 1835 (3.3%) participantsdirect smear examination or of P. falciparum DNA by
Mocuba n=720 Total (both sites) n = 1835
n (%) (%)
404 (32.0) 1280 (100)
404 1280 (100)
39 (9.6) 43 (3.3)
365 (90.4) 1237 (96.7)
204 842 (100)
37 (18.1) 49 (5.8)
167 (81.9) 793 (94.2)
316 (57) 555 (100)
316 555 (100)
16 (5.1) 17 (3.1)
300 (94.9) 538 (96.9)
183 407 (100.0)
20 (10.9) 24 (5.9)
163 (89.1) 383 (94.1)
720 (39) 1835 (100)
55 (7.6) 60 (3.2)
665 (92.4) 1775 (96.8)
387 1249 (100)
53 (13.7) 69 (6.0)
334 (86.3) 1198 (94.0)
Table 2 Sensitivity, specificity and efficiency of PCR to
detect malaria in the study population
Test Smear Total Sen. Spec. Eff.
Positive Negative
PCR Positive 38 35 73 0.90 0.97 0.97
Negative 4 1,172 1,176
Total 42 1,207 1,249
Data represent the number of positive and negative individuals results for
samples tested by both methods. Sen = Sensitivity, Spec = specifcity and
Eff = efficiency. Data are the proportion of true positive and true negative
(using the peripheral blood smear as the gold standard test).
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difference in sensitivity was driven by the HIV-1 infected
population where the rate of parasitaemia was 49/842
(5.8%) as assessed by PCR but only 43/1,280(3.4%) when
assessed by microscopy. By contrast, the rates of parasit-
aemia were comparable (~3%) in the HIV-1 uninfected
population whether assessed by microscopy or PCR.
Plasmodium falciparum DNA was detected by PCR in
38 of the 42 (90.4%) samples that were positive by mi-
croscopy. In contrast, parasites were detected by micros-
copy in only 38 of the 73 (52%) of those that had P.
falciparum DNA detected by PCR analysis.
Discussion
In this study, sub-clinical malaria was more prevalent in
HIV-1 infected individuals than in HIV-1 seronegative
populations when assayed by either smear or nested
DNA PCR. Sub-clinical parasitaemia was less frequent in
Maputo where malaria eradication efforts have been
more intensive over the past several years in comparison
with rural areas of the country. The significantly higher
rate of sub-clinical malaria in asymptomatic individuals
from Mocuba and the use of TS prophylaxis in HIV-1
infected persons with lower CD4 cell counts provided an
opportunity to evaluate the impact of TS prophylaxis on
the prevalence of sub-clinical malaria by both light mi-
croscopy and PCR. Although the practice of prescribing
TS prophylaxis primarily to those with lower CD4 cell
counts was a potential confounding factor, our dataTable 3 Effect of trimethoprim-sulphamethoxazole
prophylaxis on malarial positivity by direct smear
examination and PCR among participants enrolled in
Mocuba
On TS Not on TS TS Status Unknown Total
Smear Positive 3 (10.7%) 31 (8.4%) 5 (71.4%) 39
Smear Negative 25 (89.3%) 338 (91.6%) 2 (28.6%) 365
Total 28 369 7 404
PCR Positive 4 (14.3%) 31 (17.9%) 2 (66.7%) 37
PCR Negative 24 (85.7%) 142 (82.1%) 1 (33%) 167
Total 28 173 3 204indicate that TS prophylaxis does not eliminate sub-
clinical parasitaemia whether assessed by microscopy or
PCR. Among those who were smear positive for malaria,
more than twofold higher parasite density levels were
observed in the HIV-1 infected population than among
those who were HIV-1 seronegative, in contrast to what
has been previously reported [18]. Although both popu-
lations were recruited from people seeking care from
HIV-1 testing and treatment sites in the same clinical fa-
cilities, caution in interpreting the differences in preva-
lence and parasitaemia levels between the HIV-1
infected and HIV-1 seronegative populations is war-
ranted since other differences in the two populations
might be unrecognized.
It is also possible that the observed differences in
prevalence and levels of parasitaemia between the HIV-1
infected and uninfected populations might actually
underestimate the effect of HIV-1 infection on malarial
parasitaemia rates since HIV-1 infected individuals since
those under care for HIV might be more likely to be in
contact with the health care system and have more ac-
cess to bed nets and other preventive measures. Further-
more, since syndromic treatment of fever with empiric
anti-malarial therapy is not uncommon, persons with
fever from HIV-1 or its complications could be more
likely to receive empiric intermittent anti-malarial ther-
apy for other disease states which might further lower
the prevalence of sub-clinical malaria in this group. An
additional limitation of the study was that HIV RNA
levels are not routinely monitored in Mozambique and,
thus, viral load data were not available.
TS prophylaxis in HIV patients reduces morbidity and
mortality from malaria as well as from Pneumocystis jiro-
vecii [19,20]. In view of the low prevalence of malarial
parasitaemia and of clinical malaria in Maputo, TS
would seem to be less critical from the perspective of re-
ducing morbidity and mortality from malaria than in
places like Mocuba, where the risk of malaria remains
higher. The potential impact of TS on other HIV-1
related opportunistic infections, such as Pneumocystis
jirovecii pneumonia would, nonetheless, continue to be
important. It is well demonstrated that HIV infection
predisposes to more frequent and more severe episodes
of malaria [3,5,9,10]. Since this was a cross-sectional ra-
ther than a longitudinal study, time-dependent malaria-
related morbidity and mortality rates were beyond the
scope of this study. Nonetheless, in Mocuba where P.
falciparum elimination efforts have been less successful
than in Maputo, it was found that the HIV cohort had
1.7 times more sub-clinical malaria than the HIV unin-
fected cohort as defined by PCR. Others have demon-
strated that overt clinical bouts of malaria are associated
with increased levels of HIV-1 RNA and of CD4 cell de-
cline [6,21]. The implications of sub-clinical malarial
Noormahomed et al. Malaria Journal 2012, 11:252 Page 6 of 6
http://www.malariajournal.com/content/11/1/252parasitaemia for HIV-1 disease progression have not yet
been delineated, but it would seem that such studies are
warranted [22,23]. Finally, although the impact of sub-
clinical malarial parasitaemia on the risk of clinical mal-
aria in either the HIV-1 infected or the HIV-1 seronega-
tive population or on the progression of HIV-1 in the
co-infected population has not been fully delineated, the
sensitivity of nested PCR of dried blood spots for detect-
ing carriage of P. falciparum might make this an attract-
ive approach to monitor the success or failure of malaria
control efforts in areas, such as Mocuba, as more con-
certed efforts to eliminate malaria are undertaken.
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